Comparative Pharmacology
Head-to-head clinical analysis: BARHEMSYS versus TIGAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BARHEMSYS versus TIGAN.
BARHEMSYS vs TIGAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BARHEMSYS (amisulpride) is a selective dopamine D2/D3 receptor antagonist. It also has weak affinity for serotonin 5-HT2A and 5-HT2B receptors, with no significant activity at other dopamine or serotonin receptor subtypes. Its antiemetic effect is primarily mediated through blockade of D2 receptors in the chemoreceptor trigger zone (CTZ).
TIGAN (trimethobenzamide) acts on the chemoreceptor trigger zone (CTZ) to inhibit emetic stimuli, primarily through antagonism of dopamine D2 receptors, though its exact mechanism is not fully elucidated.
BARHEMSYS (amisulpride) 10 mg intravenously over 2 minutes, once daily for prevention of postoperative nausea and vomiting.
Adults: 200 mg IM or 100 mg PO or 200 mg PR every 6–8 hours as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily dosing in most patients.
12-15 hours; may be prolonged in hepatic impairment.
Renal excretion accounts for approximately 50% of the dose as unchanged drug; fecal elimination (including biliary) accounts for approximately 30-40%.
Renal (30-50% as unchanged drug and metabolites), biliary/fecal (minor).
Category C
Category C
Antiemetic
Antiemetic